Suppr超能文献

肾移植:哈利法克斯的经验

Kidney transplantation, the Halifax experience.

作者信息

Belitsky P, MacDonald A S, Lawen J, McAlister V, Bitter-Suermann H, Kiberd B, West K, Sketris I

机构信息

Department of Urology, Queen Elizabeth II Health Science Centre, Halifax, Nova Scotia, Canada.

出版信息

Clin Transpl. 1996:231-40.

PMID:9286572
Abstract

In the absence of a national kidney sharing system in Canada, virtually all the cadaver kidneys we transplant come from donors within the 4 provinces we serve. Currently the only criteria we use for recipient selection of cadaver kidneys, apart from ABO blood group matching and a negative anti-T-cell crossmatch, are good HLA match and transplant wait-list seniority. All transplant recipients receive CsA-based immunosuppression. Antibody induction is used only for repeat transplants and pediatric transplants. Recipients of first cadaver kidney transplants with zero HLA-DR mismatches have significantly better graft survival than those with mismatches. Graft and patient survival rates for first cadaver transplants continue to improve within the CsA era, and are comparable to those seen in centers routinely using antibody induction and routine sequential quadruple immunosuppression. Chronic graft nephropathy continues to be the most important cause of graft loss after the first year, unchanged over the past 2 decades, followed closely by death with a functioning kidney. The latter is a more important cause of loss in recipients older than age 60, and in recipients of HLA-identical live donor transplants. Repeat cadaver transplant recipients have a 5-year graft survival rate today equivalent to that seen with first cadaver transplants. Graft loss from acute rejection is modest, but kidneys requiring rescue therapy for steroid-resistant rejection have significantly poorer one- and 5-year graft survival and ultimately are lost from rejection. Patients with HLA-identical live-related donor transplants have better long-term survival with CsA than with azathioprine due to a decrease in graft loss from chronic rejection. Pre-transplant sensitization has an adverse effect on graft survival for haploidentical but not HLA identical live-related transplants. Patients over age 60 have equivalent graft survival to younger recipients for at least 7 years, and should not be precluded from receiving transplants by age alone. Prolonged CIT > 24 hours is associated with a significantly increased incidence and duration of ATN and need for dialysis, significantly increased early and late graft loss from acute and chronic rejection respectively, significantly reduced QALY's, and significantly higher early and late costs of transplantation.

摘要

在加拿大缺乏全国性肾脏共享系统的情况下,我们所移植的几乎所有尸体肾都来自我们服务的4个省份内的捐赠者。目前,除了ABO血型匹配和阴性抗T细胞交叉配型外,我们用于尸体肾受者选择的唯一标准是良好的HLA匹配和移植等待名单上的资历。所有移植受者均接受以环孢素为基础的免疫抑制治疗。抗体诱导仅用于再次移植和小儿移植。首次尸体肾移植时HLA-DR错配数为零的受者,其移植物存活率明显高于有错配的受者。在环孢素时代,首次尸体肾移植的移植物和患者存活率持续提高,与那些常规使用抗体诱导和常规序贯四联免疫抑制的中心所观察到的存活率相当。慢性移植肾病仍然是第一年之后移植物丢失的最重要原因,在过去20年中没有变化,紧随其后的是有功能肾的死亡。后者在60岁以上的受者以及HLA相同的活体供者移植受者中是更重要的丢失原因。再次尸体肾移植受者如今的5年移植物存活率与首次尸体肾移植的情况相当。急性排斥导致的移植物丢失较少,但需要针对激素抵抗性排斥进行挽救治疗的肾脏,其1年和5年移植物存活率明显较差,最终因排斥而丢失。与硫唑嘌呤相比,接受HLA相同的活体亲属供者移植的患者使用环孢素具有更好的长期存活率,这是因为慢性排斥导致的移植物丢失减少。移植前致敏对单倍型相同但HLA不相同的活体亲属移植的移植物存活有不利影响。60岁以上的患者至少7年内的移植物存活率与年轻受者相当,不应仅凭年龄就排除其接受移植的可能性。冷缺血时间(CIT)延长>24小时与急性肾小管坏死(ATN)的发生率和持续时间显著增加以及透析需求相关,分别与急性和慢性排斥导致的早期和晚期移植物丢失显著增加、质量调整生命年(QALY)显著降低以及移植的早期和晚期成本显著升高相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验